In this paper, the plasma glucose regulation problem for Type 2 diabetic patients is studied. A nonlinear time-delay model of the glucose-insulin regulatory system is exploited in order to design a sampled-datastatic...
详细信息
In this paper, the plasma glucose regulation problem for Type 2 diabetic patients is studied. A nonlinear time-delay model of the glucose-insulin regulatory system is exploited in order to design a sampled-datastaticoutputfeedback control, which makes use of only sampled glucose measurements. It is shown that the proposed control law is a stabilizer in the sampled-and-hold sense. The presence of a state-delay in the model prevents the availability in the buffer of suitable needed past values of the glucose. Such a drawback is overcome by means of spline interpolation. A pre-clinical validation, concerning the performances of the proposed glucose control law, is carried-out by means of a well known simulator of diabetic patients broadly accepted for testing insulin infusion therapies. Simulations results are encouraging for further evaluation. Copyright (C) 2020 The Authors.
In this paper, the plasma glucose regulation problem for Type 2 diabetic patients is studied. A nonlinear time-delay model of the glucose-insulin regulatory system is exploited in order to design a sampled-datastatic...
详细信息
In this paper, the plasma glucose regulation problem for Type 2 diabetic patients is studied. A nonlinear time-delay model of the glucose-insulin regulatory system is exploited in order to design a sampled-datastaticoutputfeedback control, which makes use of only sampled glucose measurements. It is shown that the proposed control law is a stabilizer in the sampled-and-hold sense. The presence of a state-delay in the model prevents the availability in the buffer of suitable needed past values of the glucose. Such a drawback is overcome by means of spline interpolation. A pre-clinical validation, concerning the performances of the proposed glucose control law, is carried-out by means of a well known simulator of diabetic patients broadly accepted for testing insulin infusion therapies. Simulations results are encouraging for further evaluation.
暂无评论